Actively Recruiting
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
Led by University of Alabama at Birmingham · Updated on 2025-05-20
80
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This will be a 6-month randomized clinical trial with two arms: moderately carbohydrate-restricted diet and a fat-restricted control diet. This 6-month study will have 2 phases: a 12-week controlled feeding phase and a 12-week "free living" phase. During the controlled feeding phase, all food will be provided to the families of the participants for the entirety of the 12 weeks. Participants (n=80) will have been diagnosed with NAFLD based on the presence of current evidence of active disease, which will be determined by the ongoing presence of hepatic steatosis estimated by diffusely echogenic liver via ultrasound suggestive of fatty liver and a serum alanine aminotransferase (ALT) level of 45 U/L or greater. All participants will be children and adolescents age 10-17 yrs.; will have an HbA1c \<7.0; and will be overweight or obese (BMI \>85th percentile). It is anticipated that most participants will be sedentary. The investigators will inquire as to routine physical activity at screening. All participants will be asked to maintain their usual level of physical activity throughout the study. Physical activity will be monitored via a smart watch provided to each participant at the beginning of the study, and participants will be queried weekly by the study dietitian regarding changes in physical activity. Participants who use oral contraceptives will be asked to maintain consistent use of these preparations throughout the study. Hormone use will be examined as a potential covariate in statistical analyses.
CONDITIONS
Official Title
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical-pathological diagnosis of NAFLD with current active disease shown by hepatic steatosis on ultrasound and ALT level of 45 U/L or higher
- Age between 10 and 17 years
- Overweight or obese with BMI above the 75th percentile
You will not qualify if you...
- Pregnancy
- HbA1c greater than 7%
- History of parenteral nutrition
- Hepatic virus infections including hepatitis A, B, C, D, E, G, cytomegalovirus, and Epstein-Barr virus
- Use of medications known to induce steatosis, elevate liver enzymes, or affect body weight and carbohydrate metabolism within the last 6 months
- Autoimmune liver disease
- Metabolic liver disease
- Wilson's disease
- Genetic conditions causing hepatic steatosis such as glycogen storage disorder
- History of bariatric surgery
- Unwillingness or inability to give consent, accept random assignment, attend counseling, adhere to treatment, or complete study measures
- Inability to speak and understand English (participant and parent/guardian)
- Currently receiving intense lifestyle modification treatment
- Estimated Glomerular Filtration Rate (eGFR) less than 60
- Use of alcohol, tobacco, or recreational drugs
- Unable to undergo MRI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35226
Actively Recruiting
Research Team
A
Alex Luzuriaga-McPherson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here